KYMR
Kymera Therapeutics, Inc.
$73.95
-0.24%
$6.3B
No data for this timeframe.
Vol
Market Cap$6.3B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$1.3B
Inst. Activity4 buys / 2 sells
Insider Activity0B / 17S
Insider Net $-$7.2M
SEC Reports12
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001815442·Prev Close $74.13
Recent Activity
Jun 8, 2026
other
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
<p align="center"><em>Penny Carlson will oversee global clinical development operations across Kymer
Jun 8, 2026
Press
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, show
Impact 6/10
Jun 2, 2026
Insider
Jacobs Bruce N. sold 12,653 shares
Chief Financial Officer @ $2.08 ($26.3K)
Jun 2, 2026
Insider
Jacobs Bruce N. sold 12,653 shares
Chief Financial Officer @ $0.00 ($0.00)
May 27, 2026
Insider
Chadwick Jeremy G sold 3,679 shares
Chief Operating Officer @ $81.50 ($299.8K)
May 26, 2026
SEC
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating intent to sell 13,130 s
144 — Impact 2/10
May 11, 2026
SEC
Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, with an estimated mark
144 — Impact 2/10
Apr 24, 2026
SEC
Two insiders at Kymera Therapeutics sold a combined $315K in shares within a 7-day window, including COO Chadwick Jeremy
CLUSTER — Impact 3/10
Price Targets
$118.55
+54.1% upside
Strong Buy
Current $76.91
Low $97.00
Median $118.50
High $140.00
22 analysts
$97.00
$140.00
Analyst Ratings
11Strong Buy
17Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 3, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 2, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 2, 2026 | Stephens & Co. | MAINTAIN | Overweight → Overweight |
| Feb 26, 2026 | BTIG | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.74 ▲ +2.2% | $-1.42 — $-0.27 | 22% YoY | 21 |
| Next Q | $-1.03 | $-1.56 — $-0.67 | -10% YoY | 20 |
| Current FY | $-3.53 ▲ +0.8% | $-5.51 — $-2.64 | 4% YoY | 21 |
| Next FY | $-4.37 | $-6.49 — $-3.21 | -24% YoY | 21 |
Latest Reports
BULLISH
Press
6/10
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, show
Jun 8, 2026
NEUTRAL
144
2/10
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating intent to sell 13,130 s
May 26, 2026
NEUTRAL
144
2/10
Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, with an estimated mark
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $694.7M | ADD |
| VANGUARD GROUP INC | $487.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $38.7M | NEW |
| BANK OF AMERICA CORP | $26.4M | ADD |
| MORGAN STANLEY | $21.3M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Jacobs Bruce | M | $26.3K |
| Jun 2, 2026 | Jacobs Bruce | M | $0.00 |
| May 27, 2026 | Chadwick Jeremy | SELL | $299.8K |
| May 26, 2026 | Chadwick Jeremy | SELL | $292.3K |
| May 19, 2026 | Esposito Pamela | M | $0.00 |
8 institutional holders with $1.3B total value (16,654,825 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,928,574 | $694.7M | 53.6% | ADD +51.9% |
| 2 | VANGUARD GROUP INC | 6,267,644 | $487.7M | 37.6% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 497,026 | $38.7M | 3.0% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 338,999 | $26.4M | 2.0% | ADD +82.0% |
| 5 | MORGAN STANLEY | 274,018 | $21.3M | 1.6% | TRIM -27.5% |
| 6 | TWO SIGMA INVESTMENTS, LP | 265,532 | $20.7M | 1.6% | TRIM -38.2% |
| 7 | WELLS FARGO & COMPANY/MN | 66,489 | $5.2M | 0.4% | DOUBLED +107.4% |
| 8 | NORGES BANK | 16,543 | $1.3M | 0.1% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 5,879,611 | 8,928,574 | +51.9% | $694.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 186,254 | 338,999 | +82.0% | $26.4M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 377,799 | 274,018 | -27.5% | $21.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 429,975 | 265,532 | -38.2% | $20.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 32,061 | 66,489 | +107.4% | $5.2M | 2025-Q4 |
| NORGES BANK | NEW | — | 16,543 | — | $1.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 159,163 | 429,975 | +170.1% | $24.3M | 2025-Q3 |
| MORGAN STANLEY | ADD | 237,605 | 377,799 | +59.0% | $21.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 134,939 | 186,254 | +38.0% | $10.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 25,571 | 32,061 | +25.4% | $1.8M | 2025-Q3 |
| NORGES BANK | EXIT | 41,370 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 172,082 | 237,605 | +38.1% | $10.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 96,805 | 134,939 | +39.4% | $5.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 41,370 | — | $1.8M | 2025-Q2 |
| UBS Group AG | ADD | 469,842 | 593,606 | +26.3% | $16.2M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 239,763 | 172,082 | -28.2% | $4.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 85,267 | 18,705 | -78.1% | $512.0K | 2025-Q1 |
| NORGES BANK | EXIT | 91,231 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 217,619 | 469,842 | +115.9% | $18.9M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 488,077 | 239,763 | -50.9% | $9.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 14,452 | 21,939 | +51.8% | $882.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 366,841 | — | $17.4M | 2024-Q3 |
7 unique insiders with 17 transactions. Net insider value: -$7.2M ($0.00 bought, $7.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Jacobs Bruce N. | Chief Financial Officer | M | 12,653 | $2.08 | $26.3K |
| Jun 2, 2026 | Jacobs Bruce N. | Chief Financial Officer | M | 12,653 | $0.00 | $0.00 |
| May 27, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 3,679 | $81.50 | $299.8K |
| May 26, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 3,730 | $78.36 | $292.3K |
| May 19, 2026 | Esposito Pamela | Director | M | 1,000 | $0.00 | $0.00 |
| May 19, 2026 | Esposito Pamela | Director | M | 1,000 | $31.20 | $31.2K |
| May 18, 2026 | Jacobs Bruce N. | Chief Financial Officer | M | 15,000 | $2.08 | $31.2K |
| May 18, 2026 | Jacobs Bruce N. | Chief Financial Officer | M | 15,000 | $0.00 | $0.00 |
| May 11, 2026 | Ridloff Elena | Director | M | 3,000 | $31.20 | $93.6K |
| May 11, 2026 | Ridloff Elena | Director | M | 3,000 | $0.00 | $0.00 |
| May 11, 2026 | Ridloff Elena | Director | SELL | 3,000 | $87.00 | $261.0K |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | M | 30,000 | $2.08 | $62.4K |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | SELL | 17,005 | $80.74 | $1.4M |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | M | 30,000 | $0.00 | $0.00 |
| Apr 22, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 100 | $30.17 | $3.0K |
| Apr 22, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 300 | $90.00 | $27.0K |
| Apr 22, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 100 | $0.00 | $0.00 |
| Apr 22, 2026 | Booth Bruce | Director | SELL | 5,900 | $89.96 | $530.8K |
| Apr 22, 2026 | Booth Bruce | Director | M | 5,641 | $14.18 | $80.0K |
| Apr 22, 2026 | Booth Bruce | Director | M | 5,641 | $0.00 | $0.00 |
| Apr 15, 2026 | Booth Bruce | Director | M | 2,200 | $0.00 | $0.00 |
| Apr 15, 2026 | Booth Bruce | Director | M | 2,200 | $14.18 | $31.2K |
| Apr 15, 2026 | Booth Bruce | Director | SELL | 2,200 | $89.95 | $197.9K |
| Apr 15, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 1,300 | $43.50 | $56.5K |
| Apr 15, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 1,300 | $90.00 | $117.0K |
| Apr 15, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 1,300 | $0.00 | $0.00 |
| Apr 14, 2026 | Booth Bruce | Director | M | 4,159 | $14.18 | $59.0K |
| Apr 14, 2026 | Booth Bruce | Director | SELL | 4,159 | $89.97 | $374.2K |
| Apr 14, 2026 | Booth Bruce | Director | M | 4,159 | $0.00 | $0.00 |
| Apr 14, 2026 | Goodman Noah | Chief Business Officer | SELL | 1,347 | $90.00 | $121.2K |
| Apr 14, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 4,466 | $30.17 | $134.7K |
| Apr 14, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 5,251 | $90.00 | $472.6K |
| Apr 14, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 4,466 | $0.00 | $0.00 |
| Apr 10, 2026 | Goodman Noah | Chief Business Officer | SELL | 2,000 | $87.35 | $174.7K |
| Apr 9, 2026 | Goodman Noah | Chief Business Officer | M | 2,500 | $21.05 | $52.6K |
| Apr 9, 2026 | Goodman Noah | Chief Business Officer | M | 2,500 | $0.00 | $0.00 |
| Apr 9, 2026 | Goodman Noah | Chief Business Officer | SELL | 3,094 | $86.62 | $268.0K |
| Apr 1, 2026 | Ridloff Elena | Director | M | 4,600 | $14.18 | $65.2K |
| Apr 1, 2026 | Ridloff Elena | Director | SELL | 3,400 | $85.19 | $289.7K |
| Apr 1, 2026 | Ridloff Elena | Director | M | 4,600 | $0.00 | $0.00 |
| Apr 1, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 14,640 | $29.64 | $433.9K |
| Apr 1, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 13,540 | $85.41 | $1.2M |
| Apr 1, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 14,640 | $0.00 | $0.00 |
| Mar 31, 2026 | Ridloff Elena | Director | M | 7,400 | $14.18 | $104.9K |
| Mar 31, 2026 | Ridloff Elena | Director | SELL | 7,400 | $85.37 | $631.7K |
| Mar 31, 2026 | Ridloff Elena | Director | M | 7,400 | $0.00 | $0.00 |
| Mar 31, 2026 | Chadwick Jeremy G | Chief Operating Officer | SELL | 7,600 | $85.38 | $648.9K |
| Mar 31, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 7,600 | $29.64 | $225.3K |
| Mar 31, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 7,600 | $0.00 | $0.00 |
| Mar 25, 2026 | Chadwick Jeremy G | Chief Operating Officer | M | 24,727 | $29.64 | $732.9K |
12 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 10 neutral. Avg impact: 3.4/10.
NEUTRAL
144
2/10
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating int
May 26, 2026
NEUTRAL
144
2/10
Director Elena Ridloff filed a Form 144 to sell 3,000 shares of Kymera Therapeutics common stock, wi
May 11, 2026
NEUTRAL
CLUSTER
3/10
Two insiders at Kymera Therapeutics sold a combined $315K in shares within a 7-day window, including
Apr 24, 2026
NEUTRAL
PRESS-RELEASE
3/10
Kymera Therapeutics (KYMR) announced it will report Q1 2026 financial results on April 30, 2026, wit
Apr 23, 2026
NEUTRAL
CLUSTER
3/10
Two corporate insiders at Kymera Therapeutics sold shares in the past week, including Director Booth
Apr 16, 2026
NEUTRAL
144
3/10
Two institutional affiliates of Atlas Venture—Atlas Venture Fund X, L.P. and Atlas Venture Opportuni
Apr 15, 2026
NEUTRAL
144
3/10
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to notify the SEC of his intent
Apr 15, 2026
NEUTRAL
144
3/10
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of
Apr 1, 2026
NEUTRAL
144
3/10
Elena Ridloff, a director at Kymera Therapeutics, filed a Form 144 to sell up to 4,600 shares, follo
Apr 1, 2026
BEARISH
CLUSTER
6/10
Kymera Therapeutics COO Chadwick Jeremy G conducted a series of derivative exercises and open-market
Mar 25, 2026
NEUTRAL
8-K
4/10
Kymera Therapeutics entered into a $500 million at-the-market (ATM) equity offering agreement with T
Feb 26, 2026
MIXED
8-K
6/10
Kymera Therapeutics reported financial results for Q4 and full year 2025, highlighted by a $692 mill
Feb 26, 2026
BULLISH
6/10
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and
Jun 8, 2026
NEUTRAL
4/10
Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID a
May 15, 2026
BULLISH
7/10
Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, sh
Mar 28, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 30 analysts: 11 strong buy, 17 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$118.55 mean target
+54.1% upside
Strong Buy (1.29)
$97.00 Low
$140.00 High
| Metric | Value |
|---|---|
| Current Price | $76.91 |
| Target Low | $97.00 |
| Target Mean | $118.55 |
| Target Median | $118.50 |
| Target High | $140.00 |
| # Analysts | 22 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.74 | $-1.42 | $-0.27 | 22.1% | +2.2% | 13↑ 2↓ | $0.0B | 175.2% | 21 |
| Next Q 2026-09-30 |
$-1.03 | $-1.56 | $-0.67 | -9.5% | -0.3% | 4↑ 11↓ | $0.0B | 181.3% | 20 |
| Current FY 2026-12-31 |
$-3.53 | $-5.51 | $-2.64 | 4.3% | +0.8% | 13↑ 4↓ | $0.1B | 111.7% | 21 |
| Next FY 2027-12-31 |
$-4.37 | $-6.49 | $-3.21 | -23.9% | -0.1% | 6↑ 10↓ | $0.0B | -54.4% | 21 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.740 | |
| 7d ago | $-0.757 | +0.017 |
| 30d ago | $-0.757 | +0.017 |
| 60d ago | $-0.898 | +0.158 |
| 90d ago | $-0.898 | +0.158 |
10 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 3, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Stephens & Co. | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 3, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 28, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 15, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 6, 2026 | Wolfe Research | DOWNGRADE | Outperform | Peer Perform |
| Dec 22, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 17 | 2 | 0 | 0 | 93% | |
| May 1, 2026 | 11 | 16 | 2 | 0 | 0 | 93% | |
| Apr 1, 2026 | 11 | 16 | 2 | 0 | 0 | 93% | |
| Mar 1, 2026 | 11 | 16 | 2 | 0 | 0 | 93% | |
| Feb 1, 2026 | 11 | 16 | 2 | 0 | 0 | 93% | |
| Jan 1, 2026 | 12 | 16 | 1 | 0 | 0 | 97% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
other
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
<p align="center"><em>Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio</em></p>
Jun 8, 2026
fda
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
<p align="center"><em>KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in
May 15, 2026
fda
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
<p align="center"><em>Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Ph
May 6, 2026
other
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
<p>WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=7NsdBI7FAeYynXGbrlGq4qREDjIaZS4dJVQ1iZOxgC
Apr 30, 2026
earnings
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
<p align="center"><em>KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-
Apr 30, 2026
earnings_calendar
KYMR Q1 2026 Earnings Scheduled — 2026-04-30
Apr 23, 2026
earnings
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
<p>WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=fUebB4Kr_fRVKOcmsUVp3HObFS5wluym2_O_lXH2
Mar 28, 2026
earnings
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
<p align="center"><em>Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral p
Mar 24, 2026
short_interest
FTD: KYMR — 83,350 shares ($6.4M) failed to deliver
Settlement: 20260324, Price: $76.96, FTD Value: $6,414,616, KYMERA THERAPEUTICS INC COM
Mar 16, 2026
short_interest
FTD: KYMR — 8,057 shares ($0.6M) failed to deliver
Settlement: 20260316, Price: $79.03, FTD Value: $636,744.71, KYMERA THERAPEUTICS INC COM
Mar 11, 2026
short_interest
FTD: KYMR — 7,299 shares ($0.6M) failed to deliver
Settlement: 20260311, Price: $84.58, FTD Value: $617,349.42, KYMERA THERAPEUTICS INC COM
Mar 5, 2026
short_interest
FTD: KYMR — 7,378 shares ($0.6M) failed to deliver
Settlement: 20260305, Price: $86.11, FTD Value: $635,319.58, KYMERA THERAPEUTICS INC COM
Feb 27, 2026
short_interest
FTD: KYMR — 16,662 shares ($1.6M) failed to deliver
Settlement: 20260227, Price: $95.03, FTD Value: $1,583,389.86, KYMERA THERAPEUTICS INC COM
Feb 26, 2026
earnings_calendar
KYMR Q4 2025 Earnings After Market Close — 2026-02-26
Feb 26, 2026
short_interest
FTD: KYMR — 20,822 shares ($1.9M) failed to deliver
Settlement: 20260226, Price: $90.68, FTD Value: $1,888,138.96, KYMERA THERAPEUTICS INC COM